Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.
   No.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission?
   No.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

<table>
<thead>
<tr>
<th>Company</th>
<th>Check</th>
<th>Dollar Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eli Lilly</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Astra Zeneca</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Jenn Gordon
Position: Director of Operations
Patient Group: Canadian Breast Cancer Network
Date: December 3, 2018
Appendix: Patient Group Conflict of Interest Declaration

To maintain the objectivity and credibility of the CADTH CDR and pCODR programs, all participants in the drug review processes must disclose any real, potential, or perceived conflicts of interest. This Patient Group Conflict of Interest Declaration is required for participation. Declarations made do not negate or preclude the use of the patient group input. CADTH may contact your group with further questions, as needed.

1. Did you receive help from outside your patient group to complete this submission? If yes, please detail the help and who provided it.

2. Did you receive help from outside your patient group to collect or analyze data used in this submission? If yes, please detail the help and who provided it.

Rethink Breast Cancer employs an outside contractor, Adam Waiser, to develop online surveys, solicit patient feedback and prepare the final submission. Potential respondents are identified with the assistance of the Young Women’s Network and Breastcancer.org as well as the Canadian and American Cancer Societies through their online discussion boards, Cancer Connection and Cancer Survivors Network.

3. List any companies or organizations that have provided your group with financial payment over the past two years AND who may have direct or indirect interest in the drug under review.

<table>
<thead>
<tr>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ely Lily</td>
</tr>
</tbody>
</table>

I hereby certify that I have the authority to disclose all relevant information with respect to any matter involving this patient group with a company, organization, or entity that may place this patient group in a real, potential, or perceived conflict of interest situation.

Name: Shawna Rich-Ginsberg  
Position: Senior Manager, Support & Education  
Patient Group: Rethink Breast Cancer  
Date: December 17th, 2018